Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant tuberculin
- Development stage
- Preclinical
- Lead developer
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
Recombinant tuberculin is a diagnostic recombinant protein candidate being developed by the Saint Petersburg Research Institute of Vaccines and Sera (SPbNIIVS) for the detection of *Mycobacterium tuberculosis* infection. It is designed as a more specific alternative to the traditional tuberculin purified protein derivative (PPD) skin test. By utilizing recombinant antigens that are specific to pathogenic *M. tuberculosis* and absent in the *Bacillus Calmette-Guérin* (BCG) vaccine strain, this diagnostic tool aims to eliminate false-positive results common in BCG-vaccinated populations. The product is currently in preclinical development and is listed as an R&D priority for the institute.
- Other names
- recombinant tuberculin allergenРекомбинантный туберкулинРекомбинантный аллерген туберкулезный
02
Targets
TCR (T cell antigen receptor complex)TLR2 (Toll-like Receptor 2)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on recombinant tuberculin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant tuberculin.